These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
7. Randomized clinical study of safety, pharmacokinetics, and pharmacodynamics of RIPK1 inhibitor GSK2982772 in healthy volunteers. Weisel K, Scott NE, Tompson DJ, Votta BJ, Madhavan S, Povey K, Wolstenholme A, Simeoni M, Rudo T, Richards-Peterson L, Sahota T, Wang JG, Lich J, Finger J, Verticelli A, Reilly M, Gough PJ, Harris PA, Bertin J, Wang ML. Pharmacol Res Perspect; 2017 Dec 17; 5(6):. PubMed ID: 29226626 [Abstract] [Full Text] [Related]
8. Single-dose bioavailability of levetiracetam intravenous infusion relative to oral tablets and multiple-dose pharmacokinetics and tolerability of levetiracetam intravenous infusion compared with placebo in healthy subjects. Ramael S, De Smedt F, Toublanc N, Otoul C, Boulanger P, Riethuisen JM, Stockis A. Clin Ther; 2006 May 17; 28(5):734-44. PubMed ID: 16861095 [Abstract] [Full Text] [Related]
9. Pharmacokinetics, safety and tolerability of intravenous ferric carboxymaltose: a dose-escalation study in volunteers with mild iron-deficiency anaemia. Geisser P, Banké-Bochita J. Arzneimittelforschung; 2010 May 17; 60(6a):362-72. PubMed ID: 20648928 [Abstract] [Full Text] [Related]
14. Assessment of Safety, Tolerability, Pharmacokinetics, and Pharmacological Effect of Orally Administered CORT125134: An Adaptive, Double-Blind, Randomized, Placebo-Controlled Phase 1 Clinical Study. Hunt H, Donaldson K, Strem M, Zann V, Leung P, Sweet S, Connor A, Combs D, Belanoff J. Clin Pharmacol Drug Dev; 2018 May 17; 7(4):408-421. PubMed ID: 28967708 [Abstract] [Full Text] [Related]
15. Pharmacokinetics and Tolerability of Obiltoxaximab: A Report of 5 Healthy Volunteer Studies. Nagy CF, Leach TS, Hoffman JH, Czech A, Carpenter SE, Guttendorf R. Clin Ther; 2016 Sep 17; 38(9):2083-2097.e7. PubMed ID: 27568215 [Abstract] [Full Text] [Related]
16. Vedolizumab Pharmacokinetics, Pharmacodynamics, Safety, and Tolerability Following Administration of a Single, Ascending, Intravenous Dose to Healthy Volunteers. Rosario M, Wyant T, Leach T, Sankoh S, Scholz C, Parikh A, Fox I, Feagan BG. Clin Drug Investig; 2016 Nov 17; 36(11):913-923. PubMed ID: 27422740 [Abstract] [Full Text] [Related]
20. Safety and tolerability of an anti-CD19 monoclonal antibody, MEDI-551, in subjects with systemic sclerosis: a phase I, randomized, placebo-controlled, escalating single-dose study. Schiopu E, Chatterjee S, Hsu V, Flor A, Cimbora D, Patra K, Yao W, Li J, Streicher K, McKeever K, White B, Katz E, Drappa J, Sweeny S, Herbst R. Arthritis Res Ther; 2016 Jun 07; 18(1):131. PubMed ID: 27267753 [Abstract] [Full Text] [Related] Page: [Next] [New Search]